BEAM Beam Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BEAM

Price (delayed)

$29.57

Market cap

$2.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.17

Enterprise value

$2.41B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a ...

Highlights
The EPS is up by 8% since the previous quarter and by 7% year-on-year
The net income has increased by 4.1% since the previous quarter
BEAM's equity is up by 9% year-on-year but it is down by 4% since the previous quarter
Beam Therapeutics's revenue has decreased by 11% YoY
BEAM's gross profit is down by 11% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://beamtx.com
Peers: OMGA

Key stats

What are the main financial stats of BEAM
Market
Shares outstanding
81.5M
Market cap
$2.41B
Enterprise value
$2.41B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.01
Price to sales (P/S)
28.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.51
Earnings
Revenue
$81.55M
EBIT
-$312.67M
EBITDA
-$294.08M
Free cash flow
-$391.86M
Per share
EPS
-$4.17
Free cash flow per share
-$4.96
Book value per share
$9.84
Revenue per share
$1.03
TBVPS
$16.33
Balance sheet
Total assets
$1.29B
Total liabilities
$511.59M
Debt
$173.98M
Equity
$778.94M
Working capital
$819.18M
Liquidity
Debt to equity
0.22
Current ratio
4.72
Quick ratio
4.65
Net debt/EBITDA
0.01
Margins
EBITDA margin
-360.6%
Gross margin
100%
Net margin
-384.6%
Operating margin
-488.4%
Efficiency
Return on assets
-23.6%
Return on equity
-40.7%
Return on invested capital
-29.5%
Return on capital employed
-29.2%
Return on sales
-383.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BEAM stock price

How has the Beam Therapeutics stock price performed over time
Intraday
5.31%
1 week
-0.34%
1 month
40.54%
1 year
-35.48%
YTD
-24.39%
QTD
22.95%

Financial performance

How have Beam Therapeutics's revenue and profit performed over time
Revenue
$81.55M
Gross profit
$81.55M
Operating income
-$398.33M
Net income
-$313.67M
Gross margin
100%
Net margin
-384.6%
Beam Therapeutics's operating margin has decreased by 43% YoY and by 2.6% QoQ
Beam Therapeutics's operating income has decreased by 27% YoY and by 4.4% QoQ
The net margin has contracted by 12% YoY but it has grown by 6% from the previous quarter
Beam Therapeutics's revenue has decreased by 11% YoY

Growth

What is Beam Therapeutics's growth rate over time

Valuation

What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
3.01
P/S
28.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.51
The EPS is up by 8% since the previous quarter and by 7% year-on-year
BEAM's equity is up by 9% year-on-year but it is down by 4% since the previous quarter
Beam Therapeutics's revenue has decreased by 11% YoY
BEAM's price to sales (P/S) is 10% lower than its last 4 quarters average of 31.9

Efficiency

How efficient is Beam Therapeutics business performance
The return on sales has declined by 13% year-on-year but it is up by 5% since the previous quarter
The company's return on assets fell by 6% YoY but it rose by 2.9% QoQ
The ROE has increased by 6% QoQ but it has decreased by 2.3% YoY
BEAM's ROIC is up by 2.6% YoY and by 2.3% QoQ

Dividends

What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAM.

Financial health

How did Beam Therapeutics financials performed over time
The total assets is 152% more than the total liabilities
Beam Therapeutics's total liabilities has decreased by 20% YoY and by 6% QoQ
BEAM's current ratio is down by 10% QoQ
The debt is 78% less than the equity
The company's debt to equity fell by 12% YoY
BEAM's equity is up by 9% year-on-year but it is down by 4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.